Galit Avior
YOU?
Author Swipe
View article: Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data
Surgical Outcomes Following Neoadjuvant‐Targeted Therapy for Advanced Differentiated Thyroid Cancer—Real‐World Data Open
Background Differentiated thyroid carcinoma (DTC) is typically managed surgically with favourable outcomes. However, surgery may have dire consequences when the tumour invades critical structures. Neoadjuvant therapy with tyrosine kinase i…
View article: Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing
Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing Open
Objective The 2023 Bethesda System update introduced molecular testing as a management option for Bethesda V cytology nodules, aiming to guide surgical decision‐making. This study investigates the correlation between molecular profiling an…
View article: Cost effectiveness analysis of BRAF testing for low-risk papillary thyroid microcarcinomas
Cost effectiveness analysis of BRAF testing for low-risk papillary thyroid microcarcinomas Open
In conclusion, this study demonstrates the economic and clinical advantages of incorporating BRAFV600E genetic testing in the management of lrPTMCs. Our model supports further real-life studies of BRAFV600E testing for lrPTMCs.
View article: SAT527 The Management Of Thyroid Cancer: Where We Started And Where We Are Heading? A Five-decades Text Mining Analysis
SAT527 The Management Of Thyroid Cancer: Where We Started And Where We Are Heading? A Five-decades Text Mining Analysis Open
Disclosure: I. Tessler: None. N.A. Gecel: None. G. Avior: None. E. Klang: None. E. Alon: None. T. Kolitz: None. Aim: Thyroid cancer prevalence rate continues to increase, being the most common endocrine cancer. During the years, significan…
View article: Investigation of genetic sex‐specific molecular profile in well‐differentiated thyroid cancer: Is there a difference between females and males?
Investigation of genetic sex‐specific molecular profile in well‐differentiated thyroid cancer: Is there a difference between females and males? Open
Background Although more common in females, thyroid cancer is deemed to be more aggressive in males. The reasons for sex disparities in thyroid cancer are not well understood. We hypothesised that differences in molecular mutations between…
View article: Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis
Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis Open
Molecular testing for thyroid nodules has been rapidly developed in recent years, aiming to predict the presence of malignancy and aggressive features. While commonly utilized to predict malignancy, its role in guiding the management appro…
View article: BRAFV600E testing for low-risk papillary thyroid microcarcinomas -- Computational model from a patient-oriented approach
BRAFV600E testing for low-risk papillary thyroid microcarcinomas -- Computational model from a patient-oriented approach Open
Background: Given the good prognosis of low-risk papillary thyroid microcarcinomas (lrPTMCs) accurate risk stratification is valuable to optimize management: active surveillance vs. surgery. BRAFV600E testing was associated with increased …
View article: Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy
Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy Open
Objective: The aim of this study was to ascertain the relationship between Bethesda category and molecular mutation of thyroid nodules in patients undergoing thyroidectomy. Design: A retrospective cohort of patients who underwent thyroidec…
View article: Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: A retrospective chart review
Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: A retrospective chart review Open
Background Molecular testing has been used for cytologically indeterminate thyroid nodules (Bethesda III and IV), where the risk of malignancy is 10–40%. However, to date, the role of molecular testing in cytologically suspicious or positi…
View article: Additional file 1 of Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review
Additional file 1 of Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review Open
Additional file 1.
View article: Molecular mutations as a possible factor for determining extent of thyroid surgery
Molecular mutations as a possible factor for determining extent of thyroid surgery Open
Background Molecular testing of thyroid nodules is a diagnostic tool used to better understand the nature of thyroid nodules. The aim of this study is to better comprehend the relationship between specific mutations and aggressive behavior…
View article: MOESM1 of Molecular mutations as a possible factor for determining extent of thyroid surgery
MOESM1 of Molecular mutations as a possible factor for determining extent of thyroid surgery Open
Additional file 1. Krasner et al. raw data bank.